Switching to E-Cigarettes and Heated Tobacco Products Reduces Vascular Damage and Smoking-Related Illnesses: Study

Aug.16.2022
Switching to E-Cigarettes and Heated Tobacco Products Reduces Vascular Damage and Smoking-Related Illnesses: Study
CoEHAR researchers found using e-cigarettes and heated tobacco products can reduce smoking-related diseases. Their study challenges misconceptions about vaping.

Researchers from the Center of Excellence for the Acceleration of Harm Reduction (CoEHAR) involved in the Replica project have discovered that switching to electronic cigarettes and heated tobacco products can reduce the incidence of vascular damage and smoking-related diseases. The findings challenge the prevailing misconception that using e-cigarettes and heated tobacco products is just as harmful as smoking.


The study has been published by an independent laboratory affiliated with the Replica Project, whose scientists are world leaders in harm reduction. The latest research assessed the damage caused to endothelial cells, which release substances that control the dilation and contraction of blood vessels, by cigarette smoke compared to electronic cigarettes and heated tobacco products.


Damage to the inner lining of blood vessels known as endothelial damage is a primary pathology that leads to diseases such as atherosclerosis, with smoking being the main culprit. Smoking can impair the normal function of the endothelium, cause damage to the vascular system, and lead to the development of high blood pressure and atherosclerosis. Smoking and exposure to smoke toxins are related to the impairment of the repair mechanism needed for endothelial homeostasis, such as the inhibition of endothelial cell migration.


Reducing exposure to smoke toxins may mitigate the harmful effects on endothelial and cardiovascular disease development. Numerous international studies have investigated the impact of smoking on endothelial cell migration and associated vascular damage, particularly a study by Taylor et al. (2017). Compared to cigarette smoke, exposure to electronic cigarette aerosol significantly reduces inhibition of in vitro (in a test tube) endothelial cell migration. This means that endothelial cells exposed to electronic cigarette aerosol retain their ability to effectively heal small wounds in blood vessels, unlike those exposed to cigarette smoke and toxins, which severely limit their wound repair capacity.


One of CoEHAR's most successful projects is the Replica project, in which researchers have replicated some of the most significant international studies in the field of reducing tobacco harm via an independent laboratory network. They have demonstrated a reduction in the toxicity of electronic cigarettes and have established reference standards for scientific research. The goal of CoEHAR's scientists is to conduct a multicenter replication study to validate the results of Taylor and his colleagues.


A study titled "Comparative evaluation of e-cigarette aerosol and cigarette smoke on endothelial cell migration: a replication study" compared the effects of three commercial e-cigarette delivery systems and traditional cigarettes. Following international scientific standards and utilizing the latest technology and tools, the data collected by researchers at CoEHAR confirmed the findings of Taylor and colleagues: e-cigarettes do not induce inhibition of endothelial cell migration in vitro compared to cigarette smoke, thus reducing harm caused by tobacco smoke. Furthermore, CoEHAR researchers compared the results of two different heated tobacco products, which demonstrated significantly less impact than observed with cigarette smoke.


According to Professor Massimo Caruso, co-project leader of the Replica initiative, "As previously demonstrated by the Replica research team, the harm caused by electronic nicotine delivery systems is significantly lower than the harm caused by cigarette smoke. An interesting fact is that using non-combustible products can reduce vascular damage and prevent the likelihood of smoking-related diseases such as atherosclerosis and hypertension. Our research once again challenges the notion that electronic cigarettes or heated tobacco will cause similar damage to combustible cigarettes.


Statement:


This article is compiled from third-party information and is only meant for industry-related communication and learning purposes.


This article does not represent the views of 2FIRSTS and 2FIRSTS cannot confirm the truthfulness and accuracy of its content. The translation of this article is only intended for industry exchange and research.


Due to limitations in the translation process, the translated article may not fully reflect the original expression. Therefore, please refer to the original article for accuracy.


2FIRSTS is fully aligned with the Chinese government on any domestic, Hong Kong, Macau, Taiwan, and foreign-related statements and positions.


The compilation of information is subject to the copyright ownership of the original media outlet and author. If there is any infringement, please contact us to request removal.



Disclaimer

This article is provided solely for professional research, industry discussion, and informational purposes. Any references to brands, companies, products, technologies, or policies are made for factual reporting and analytical purposes only, and do not constitute endorsement, recommendation, promotion, or advertising by 2Firsts.

Nicotine-containing products, including but not limited to cigarettes, e-cigarettes, heated tobacco products, and nicotine pouches, carry significant health risks. Readers are responsible for complying with all applicable laws and regulations in their respective jurisdictions, including age restrictions and access limitations.

The information contained in this article should not be regarded as investment, legal, medical, regulatory, or commercial advice. While 2Firsts strives to ensure the accuracy and reliability of its content, it does not assume liability for any direct or indirect loss arising from errors, omissions, inaccuracies, or reliance on the information contained herein.

This article is not intended for individuals below the legal age for accessing tobacco or nicotine-related information in their jurisdiction.

 

Copyright Notice

This article is either original content produced by 2Firsts or content reproduced, translated, summarized, or adapted from third-party sources with attribution where applicable. The intellectual property rights of the original content remain with 2Firsts or the respective original rights holders.

No individual or organization may copy, reproduce, distribute, republish, modify, translate, or otherwise use this content without prior authorization. Any unauthorized use may result in legal action.

For copyright-related inquiries, corrections, or removal requests, please contact: info@2firsts.com.

 

AI-Assisted Translation and Editing Notice

Portions of this article may have been translated, edited, or reviewed with the assistance of artificial intelligence tools to improve efficiency and readability. Due to the limitations of AI-assisted translation and editing, discrepancies, omissions, or inaccuracies may exist when compared with the original source.

Where applicable, readers are advised to refer to the original source for the most complete and accurate information. If you identify any errors or believe that any content infringes upon your rights, please contact us at info@2firsts.com, and we will review and address the matter promptly.

Special Report | Can Nicotine Be Replaced? 6-MN Is Already on the Market While Key Human Evidence Is Still Missing
Special Report | Can Nicotine Be Replaced? 6-MN Is Already on the Market While Key Human Evidence Is Still Missing
Nicotine analogues such as 6-methylnicotine are already appearing in e-cigarettes and oral pouches, even as key human evidence remains limited. A new Nixodine-S study adds nonclinical data showing differences from nicotine in cytotoxicity and receptor activity, while independent studies point to a more complex toxicological picture. With supply-chain activity growing and FDA seeking clearer authority over nicotine analogues, the industry now faces a larger question: what evidence is needed before these substances can credibly replace nicotine?
SCIENCE
Sep.23
South Korea Imports 12,126 Kg of Nicotine Analogues From April to August After Bringing Synthetic Nicotine Under Tobacco Law
South Korea Imports 12,126 Kg of Nicotine Analogues From April to August After Bringing Synthetic Nicotine Under Tobacco Law
South Korea's liquid-vape market is showing changes across raw-material imports, product types and sales channels after synthetic nicotine came under the Tobacco Business Act on April 24. Customs data show nicotine-analogue imports totaled 12,126 kilograms from April through August, while synthetic-nicotine imports over the same five months totaled 231,663 kilograms, just 39.3% of the amount imported in March alone. Physical liquid-vape stores tracked in Seoul and Gyeonggi Province fell 9.9%, unmanned outlets edged higher and online sales listings increased from 27,774 to 42,437. Government testing of 105 liquid inhalation products promoted as nicotine-free separately found nicotine in 13 and 6-methylnicotine in 12.
Sep.22
FDA Authorizes 24 VELO Nicotine Pouches, Increasing U.S. Authorized Total by 56%
FDA Authorizes 24 VELO Nicotine Pouches, Increasing U.S. Authorized Total by 56%
The U.S. FDA authorized 24 VELO nicotine pouch products from a British American Tobacco subsidiary, raising the total number of authorized products from 43 to 67, a 55.8% increase. The newly authorized 4 mg products include lime and passion fruit flavors and feature certified child-resistant packaging. VELO's first FDA marketing authorization adds BAT to a list previously limited to PMI and Altria products, while bringing the agency's nicotine pouch review pilot total to 47 authorized products.
Oct.30
BAT Adds Former Apple General Counsel Bruce Sewell to Board as Finance, Legal, Marketing and Regional Leadership Shift
BAT Adds Former Apple General Counsel Bruce Sewell to Board as Finance, Legal, Marketing and Regional Leadership Shift
British American Tobacco has appointed former Apple Senior Vice President, General Counsel and Secretary Bruce Sewell as an independent non-executive director, effective January 1, 2027. He will also join BAT's Audit and Nominations Committees. BAT Chair Luc Jobin highlighted Sewell's experience in technology, government and regulatory affairs, public-company governance and AI-company boards. Over the past 18 months, BAT has changed or announced changes to its CFO, general counsel, CMO and APMEA regional leadership, while the main board has also seen multiple changes. The appointment comes as BAT advances Horizon 2030 and its Fit2Win transformation while expanding New Categories and reshaping parts of its digital, technology and operating structure.
Business
Oct.29
Product | OXVA Introduces XLIM PRO 4 With Liquid-Level Anti-Burn Technology and Dedicated Pods
Product | OXVA Introduces XLIM PRO 4 With Liquid-Level Anti-Burn Technology and Dedicated Pods
Vaping brand OXVA introduced the XLIM PRO 4 refillable pod system in October 2026, featuring Anti-Burn Tech (ABT) based on smart e-liquid-level detection. The system can issue refill alerts and stop power output when e-liquid levels become too low. ABT requires the XLIM PRO 4 device and a dedicated XLIM ABT cartridge. Standard XLIM pods remain compatible but do not support ABT protection. OXVA previously introduced temperature-based anti-burn technology in the XLIM Pro 2 DNA, developed with Evolv. The new device features a 1,800mAh battery, 5–30W output and a 0.98-inch HD color screen. OXVA's official store lists the device at $37.90 and dedicated ABT replacement cartridges at $12.99. Independent testing confirmed the low-liquid protection response but recorded varying cartridge lifespans.
product
Oct.30
GAO Audit Finds Nearly 132,000 FDA Tobacco Applications Waiting an Average 1,266 Days as Nicotine Pouch Pilot Practices Move Into Vape PMTA Reviews
GAO Audit Finds Nearly 132,000 FDA Tobacco Applications Waiting an Average 1,266 Days as Nicotine Pouch Pilot Practices Move Into Vape PMTA Reviews
A U.S. Government Accountability Office audit found that 131,915 tobacco product applications submitted to the FDA since 2018 remained without a final review as of December 31, 2025, with pending applications waiting an average of 1,266 days. GAO also found FDA lacks the data needed to systematically determine whether scientific reviews meet applicable timelines. HHS agreed to upgrade the agency's tracking systems. At the same time, FDA has begun applying lessons from its nicotine pouch PMTA pilot to e-cigarette reviews, while changes to enforcement policy and electronic submissions are making the specific stage of a PMTA increasingly relevant to market access.
FDA
Oct.03